Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
about
Normal physiology and HIV pathophysiology of human T-cell dynamicsBarriers to a cure for HIV in womenEmerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsCharacterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitroViral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDSAntiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1Proteomic analysis of HIV-infected macrophagesHuman immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapyInhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA constructEvolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virusStructured intermittent treatment for HIV disease: Necessary concession or premature compromise?Monitoring patients with HIV diseaseRapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues.Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assayRecovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels.Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in miceDetection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA loadChallenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.Influence of follicular dendritic cells on HIV dynamics.HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.Generation of HIV latency in humanized BLT mice.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infectionReversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infectionHuman T cell reconstitution in DiGeorge syndrome and HIV-1 infection.Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.Cell-associated HIV RNA: a dynamic biomarker of viral persistence.Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.Tissue reservoirs of HIVBiphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.
P2860
Q24630194-EFD78E5B-6D3C-41FF-B648-FEAE5EED5392Q26768632-01F2EEE1-C9CA-4DB4-B770-751BEA69B2AAQ26996159-63B98D10-EF8D-4C46-B9FA-89D8A3E91CD9Q28371764-6C01E37D-2953-4B22-9C85-E2002274E241Q33676630-105FB085-A741-4202-BAB0-9EB3B6515DEDQ33700962-FA7044A4-85DE-4E56-B9F6-E27F92CECD06Q33770687-601BF82E-1542-473E-9C3E-858125C54ADEQ33782492-925BAEF5-C032-48B1-B6C2-ABFB6A419B5CQ33822538-7A33EBF8-85D2-4084-9B4F-7E15BD524057Q33823310-C3721007-44FC-466B-A3B8-9EA1C68F3A7DQ33842020-F977CC39-8F63-4E00-8371-C1D9A89AAE06Q33896112-C2767CB9-49AA-436A-B3FE-87AEFA427444Q33925492-12C7105E-45B8-4206-895E-8DBE1CFC9F1DQ33936651-C7FA3DDB-9F8A-4D1B-B18D-0DBBD3654E3DQ33959997-B9A93255-9409-49BF-9E46-19361983D66CQ33971820-9419C08C-40EB-4732-9D70-D0CFB511402AQ33974840-9A54D6B6-6520-432C-B064-285F1B583806Q34138487-905B7021-A041-4C05-88A7-606324B774D7Q34194501-E967FDC1-A6CF-4BFB-8ED0-ED769FEA5960Q34203175-D7A46FD3-E53C-4DCB-B141-A57A951A55F7Q34348055-4CE820D7-B40D-4ADA-B075-6479C239BF41Q34720281-3BF7E864-B35B-4F5D-8DB7-BA3795C24AC6Q34869449-1C6C5FD8-BD5F-46EF-882C-F9C36C297552Q35212759-885848CC-C319-4098-A71D-3799C69C1F04Q35557244-29AFAF23-A6D5-423A-B803-47E69CC0C710Q35666126-B487BF60-28E6-4D6C-A48F-F4A03F866A9CQ35698144-5CD90836-C197-4CD4-8A70-A7984D3AFB33Q35729054-925472A7-FC40-4D71-89AE-A20883199F74Q35742512-D63843E1-27CB-4782-8F23-A8395AD1940EQ35745547-0C7120B1-4C12-4A07-BA9E-B43E5CBA65C9Q36339159-4C3BF1CA-D971-4F68-B3A2-A25E97AA38D5Q36357187-08702D58-2513-4BF0-914A-A17B899C916FQ36369965-C07652CB-A06E-4610-B277-DC1689158843Q36773750-63F7F038-264F-4DDA-BD8D-901E8889A395Q36783073-31269763-F3B4-4393-8323-6AFA10E0D004Q36783609-6A3EF768-4E35-436F-959A-A80BF279C489Q36798408-6A672FA2-12A4-40D7-B6DC-87918BDC254DQ37013364-A3F3DF8B-F66C-489B-9273-7BEC970A03DFQ37055454-92D771D2-39FD-4F84-AADA-BCFC5639FF2BQ37072991-07B75BF1-A352-465D-B2DB-97B833D4F0CC
P2860
Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Reduction of HIV-1 in blood an ...... rrelates of treatment failure.
@en
type
label
Reduction of HIV-1 in blood an ...... rrelates of treatment failure.
@en
prefLabel
Reduction of HIV-1 in blood an ...... rrelates of treatment failure.
@en
P2093
P2860
P921
P356
P1476
Reduction of HIV-1 in blood an ...... orrelates of treatment failure
@en
P2093
C C Ignacio
D D Richman
D V Havlir
P2860
P304
12574-12579
P356
10.1073/PNAS.94.23.12574
P407
P577
1997-11-01T00:00:00Z